NCT03657446View on ClinicalTrials.gov

A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 18, 2018

Primary Completion Date

October 26, 2018

Study Completion Date

October 26, 2018

Conditions
Healthy Subjects
Interventions
DRUG

Clazosentan

Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h

DRUG

Placebo

Matching placebo infusion

DRUG

Moxifloxacin

Film-coated tablet containing 400 mg moxifloxacin

Trial Locations (1)

9713 GZ

QPS Netherlands B.V., Groningen

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY